Moreover, Hartenbach et al. from the Medical University of Vienna reported the clinical impact and staging performance of hybrid multiparametric 68Ga-PSMA-HBED-CC/18F-fluorocholine PET/MRI (dtPET/MRI) in 87 patients with biopsy-proven prostate cancer scheduled for radical prostatectomy included in a prospective clinical trial (NCT02659527) [27]. This evidence concerns the gene FOLH1 and prostate carcinoma.